An analysis of the incidence and survival rates of bone sarcoma patients in thailand: reports from population-based cancer registries 2001–2015

2022 ◽  
Vol 76 ◽  
pp. 102056
Author(s):  
Jeerawan Klangjorhor ◽  
Donsuk Pongnikorn ◽  
Areerak Phanphaisarn ◽  
Parunya Chaiyawat ◽  
Pimpisa Teeyakasem ◽  
...  
Keyword(s):  
Survival Rates ◽  
Bone Sarcoma ◽  
Cancer Registries ◽  
Population Based

Outcomes of patients older than 60 years with acute lymphoblastic leukemia: Survey from the Surveillance, Epidemiology, and End Results (SEER) program.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 6532-6532
Author(s):  
Jae Hong Park ◽  
Sean Devlin ◽  
Martin S. Tallman ◽  
Dan Douer
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Survival Rates ◽  
Early Death ◽  
Cancer Registries ◽  
Population Based ◽  
Time Period ◽  
Outcome Information ◽  
Actuarial Methods ◽  
Poor Tolerance

6532 Background: The cure rate of pediatric acute lymphoblastic leukemia (ALL) has increased over the last 4 decades to above 80%, compared to a much smaller improvement in adults aged < 60 years. However, outcome information on older ALL patients (age ≥ 60 years) is limited. Only a few clinical trials include the older patients, apply the same regimens developed for adults of all ages, and report a very poor outcome with no improvement over time. We therefore conducted a population-based survey of older ALL patients focusing on early death (ED) rates and changes in outcome over the last 30 years. Methods: Data from 9 population-based cancer registries that participate in the National Cancer Institute’s SEERprogram were used to identify patients aged 60 or older with a diagnosis of ALL. Survival rates at 1, 6, 12 and 24 months were estimated using actuarial methods for 4 calendar periods: 1980-1985, 1986-1992, 1993-1999, and 2000-2006. ED was defined as death occurring within one month of ALL diagnosis. Results: A total of 1066 ALL patients were identified. The ED rate significantly improved over the four study time periods from 20.2% in 1980-1985 to 13.2% in 2000-2006 (p=0.03). The overall survival (OS) at 6 months improved from 32.8% in 1980-1985 to 45.3% in 2000-2006, but at 24 months, only a modest difference in OS was noted across the time period (13.1% in 1980-85 vs. 17.5% in 2000-06). The median survival increased from 3 months to 6 months from the period 1980-1999 to 2000-2006. Conclusions: Although the long-term OS for patients aged 60 and over remains poor, there has been a slight improvement in early mortality and median OS from 1980s to the early 21st century. While the progress in reducing ED and increasing survival at 6 months is encouraging, and may be reflecting better supportive care measures, the limited improvement indicates poor tolerance and lack of efficacy of the toxic, long and complex chemotherapy regimens designed for younger adults. Therefore, future studies should be designed specifically for older ALL patients, focusing on novel, effective, but less toxic therapies, to further improve the short-term OS seen in the past decades and possibly a better overall outcome.

Interpreting Survival Differences and Trends

1997 ◽  
Vol 83 (1) ◽  
pp. 9-16 ◽  
Author(s):  
Franco Berrino ◽  
Andrea Micheli ◽  
Milena Sant ◽  
Riccardo Capocaccia
Keyword(s):  
Early Diagnosis ◽  
Survival Data ◽  
Survival Rates ◽  
Relative Survival ◽  
Cancer Registries ◽  
Population Based ◽  
Disease Stage ◽  
Definition Of ◽  
Survival Differences ◽  
Over Time

Since 1990 a concerted action between European population-based cancer registries (the EUROCARE project) has been carried out with the aims of establishing whether there are differences in cancer patient survival in Europe, and the reasons for such differences. Survival differences actually exist for cancer sites for which the stage of disease at diagnosis is the major prognostic factor (such as breast, stomach and colon cancer). However, for most cancer sites, survival increases over time and the survival rates of different countries tend to converge towards higher values. Interpreting survival differences and trends is not an easy task. Longer survival may be achieved by postponing death through better treatment or by anticipating diagnosis. However, an earlier diagnosis may or may not make a treatment more effective in postponing death. The computation of stage-specific or stage-adjusted survival is not sufficient for interpretation of survival differences, because staging procedures change over time and may vary in different hospitals and countries. In addition to an early diagnosis and more effective treatment, a number of factors may bias survival estimates. They may be classified into factors that can be controlled in the analysis (at least partially), such as mortality from other causes, demographic factors, epoch of diagnosis, different statistical methodology, and factors depending on the validity of cancer registry data, such as definition of the illness, exhaustiveness and quality of registration, completeness of follow-up, definition of the date of diagnosis, and definition of disease stage including the diagnostic procedure used to establish stage. To help disentangle the effects of early diagnosis and better treatment, several statistical approaches are being developed: multivariate analysis on relative survival data, new modeling analysis to separately estimate the proportion of cured patients and the length of survival for those patients destined to die, and the standardized collection of information on stage at diagnosis and staging procedures.

DYNAMICS OF OBSERVED AND RELATIVE SURVIVAL OF COLON CANCER PATIENTS IN ST. PETERSBURG AND THE REPUBLIC OF BELARUS (ACCORDING TO POPULATION-BASED CANCER REGISTRIES)

2017 ◽  
Vol 63 (3) ◽  
pp. 394-405
Author(s):  
Vakhtang Merabishvili ◽  
Aleksey Okeanov ◽  
Alesya Yevmenenko
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Survival Rates ◽  
Cancer Control ◽  
Relative Survival ◽  
Cancer Registries ◽  
Population Based ◽  
Problem Analysis ◽  
The Republic ◽  
Analysis Of Dynamics

Actuality of problem. Analysis of observed and relative survival is related to important criteria for evaluation of cancer control at the population-based level covering all patients on the administrative territory as well as the group of treated patients. Comparison of the effectiveness of treatment of patients in different countries allows revealing more adequate methods of complex anti-cancer activities. In this paper such study was carried out with respect to colon cancer according to population-based cancer registries of the Republic of Belarus and St. Petersburg. Purpose of study is to compare dynamics of observed and relative survival rates in colon cancer patients in the Republic of Belarus and St. Petersburg. Materials and methods. In the basis of the study there were taken databases of population-based cancer registries of the Republic of Belarus and St. Petersburg and also there was used standard methodology by constructing expectancy tables and estimating the significance of differences in rates. Analysis of obtained data. There was performed in-depth comparative analysis of dynamics of survival rates by sex, age and histological tumor types. Conclusion. Conducted comparative study of survival colon cancer patients in the Republic of Belarus and St. Petersburg showed significant growth of rates however relative survival in Europe was much higher than in the Republic of Belarus and western regions of Russia.

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs

Blood ◽  
2008 ◽  
Vol 112 (1) ◽  
pp. 45-52 ◽  
Author(s):  
Dana E. Rollison ◽  
Nadia Howlader ◽  
Martyn T. Smith ◽  
Sara S. Strom ◽  
William D. Merritt ◽  
...  
Keyword(s):  
United States ◽  
Myelodysplastic Syndromes ◽  
Survival Rates ◽  
Myeloproliferative Disorders ◽  
Cancer Registries ◽  
The United States ◽  
Population Based ◽  
Incidence Rates ◽  
Chronic Myeloproliferative Disorders ◽  
The North

Abstract Reporting of myelodysplastic syndromes (MDSs) and chronic myeloproliferative disorders (CMDs) to population-based cancer registries in the United States was initiated in 2001. In this first analysis of data from the North American Association of Central Cancer Registries (NAACCR), encompassing 82% of the US population, we evaluated trends in MDS and CMD incidence, estimated case numbers for the entire United States, and assessed trends in diagnostic recognition and reporting. Based on more than 40 000 observations, average annual age-adjusted incidence rates of MDS and CMD for 2001 through 2003 were 3.3 and 2.1 per 100 000, respectively. Incidence rates increased with age for both MDS and CMD (P < .05) and were highest among whites and non-Hispanics. Based on follow-up data through 2004 from the Surveillance, Epidemiology, and End Results (SEER) Program, overall relative 3-year survival rates for MDS and CMD were 45% and 80%, respectively, with males experiencing poorer survival than females. Applying the observed age-specific incidence rates to US Census population estimates, approximately 9700 patients with MDS and 6300 patients with CMD were estimated for the entire United States in 2004. MDS incidence rates significantly increased with calendar year in 2001 through 2004, and only 4% of patients were reported to registries by physicians' offices. Thus, MDS disease burden in the United States may be underestimated.

scholarly journals Potential to Improve Therapy of Chronic Myeloid Leukemia (CML), Especially for Patients with Older Age: Incidence, Mortality, and Survival Rates of Patients with CML in Switzerland from 1995 to 2017

Cancers ◽  
2021 ◽  
Vol 13 (24) ◽  
pp. 6269
Author(s):  
Michael Daskalakis ◽  
Anita Feller ◽  
Jasmine Noetzli ◽  
Nicolas Bonadies ◽  
Volker Arndt ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Older Patients ◽  
Myeloid Leukemia ◽  
Survival Rates ◽  
Age Groups ◽  
Cancer Registries ◽  
Population Based ◽  
Older Age ◽  
Similar Data ◽  
Real World Data

Background: Tyrosine kinase inhibitors (TKI) substantially improved chronic myeloid leukemia (CML) prognosis. We aimed to describe time period- and age-dependent outcomes by reporting real-world data of CML patients from Switzerland. Methods: Population-based incidence, mortality, and survival were assessed for four different study periods and age groups on the basis of aggregated data from Swiss Cantonal Cancer Registries. Results: A total of 1552 new CML cases were reported from 1995 to 2017. The age-standardized rate (ASR) for the incidence remained stable, while the ASR for mortality decreased by 50–80%, resulting in a five-year RS from 36% to 74% over all four age groups. Importantly, for patients <60 years (yrs), the five-year RS increased only in earlier time periods up to 92%, whereas for older patients (+80 yrs), the five-year RS continued to increase later, however, reaching only 53% until 2017. Conclusions: This is the first population-based study of CML patients in Switzerland confirming similar data compared to other population-based registries in Europe. The RS increased significantly in all age groups over the last decades after the establishment of TKI therapy. Interestingly, we found a more prominent increase in RS of patients with older age at later observation periods (45%) compared to patients at younger age (10%), implicating a greater benefit from TKI treatment for elderly occurring with delay since the establishment of TKI therapy. Our findings suggest more potential to improve CML therapy, especially for older patients.

scholarly journals Epidemiology and survival rates of patients with malignant tumors in the Russian Federation

2021 ◽  
Author(s):  
Vakhtang M. Merabishvili
Keyword(s):  
Russian Federation ◽  
Cancer Incidence ◽  
Malignant Tumors ◽  
Survival Rates ◽  
Public Health Problem ◽  
Federal District ◽  
Cancer Registries ◽  
Population Based ◽  
Important Public Health Problem ◽  
The Russian Federation

Malignant tumors remain the most important public health problem in the world, being the second or even the leading cause of death in some countries. Cancer incidence is greatly influenced by the ever-increasing environmental hazards. Population-based Cancer Registries (PCRs) provide necessary data to monitor and assess cancer incidence. PCRs collect obligatory data on incidence rate with time series analysis, mortality and survival rates in patients diagnosed with malignant tumors. The study presents the results of the operation of PCRs as exemplified in the analysis of the PCR of Saint Petersburg and the Northwestern Federal District of the Russian Federation.

scholarly journals Epidemiology of Soft Tissue Sarcoma and Bone Sarcoma inItaly: Analysis of Data from 15 Population-Based Cancer Registries

Sarcoma ◽  
2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Sabrina Fabiano ◽  
Paolo Contiero ◽  
Giulio Barigelletti ◽  
Anna D’Agostino ◽  
Andrea Tittarelli ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Incidence Rate ◽  
Central Italy ◽  
Soft Tissue Sarcomas ◽  
Bone Sarcoma ◽  
Cancer Registries ◽  
Population Based ◽  
South Italy ◽  
The North

Sarcomas are a heterogeneous group of rare cancers of mesenchymal origin. In this study, we provide updated, world age-standardised incidence rate (ASR) and European age-standardised incidence rate for malignant soft tissue sarcoma (ICD-O-3 topographic code C47–C49) and bone sarcoma (C40, C41) in Italy, by area (north, centre, and south) and by cancer registry. We also assess morphology in relation to site and area and assess metastases at diagnosis. We analysed 1,112 cases, with incidence 2009–2012, provided by 15 cancer registries (CRs) affiliated to the Association of Italian Cancer Registries (AIRTUM). Overall, ASR was 1.7/100,000/year for soft tissue sarcoma and 0.7 for bone sarcoma. Central Italy had the highest (2.4) ASR and south Italy had the lowest (1.6) ASR for soft tissue sarcoma. Central Italy had the highest (1.1) ASR and north Italy had the lowest (0.7) ASR for bone sarcoma. By CR, ASRs ranged from 1.1 to 2.6 for soft tissue sarcoma and from 0 to 1.4 for bone sarcoma. The most frequent soft tissue sarcomas were sarcoma not otherwise specified (NOS) (29.4%) and liposarcoma (22.2%); the most common bone sarcoma was chondrosarcoma (37.6%). Soft tissue sarcomas occurred most frequently (35.6%) in lower limb connective tissue; bone sarcomas arose mainly (68.8%) in long bones. The frequencies of morphologies arising at different sites varied considerably by Italian area; for example, 20% of hemangiosarcomas occurred in the head and neck in south Italy with 17% at this site in the centre and 6% in the north. For soft tissue sarcoma, the highest ASRs of 2.6 and 2.4 contrast with the lowest ASRs 1.1 and 1.3, suggesting high-risk hot spots that deserve further investigation. The marked variations in morphology distribution with site and geography suggest geographic variation in risk factors that may also repay further investigation particularly since sarcoma etiology is poorly understood.

Trends in colorectal cancer incidence in India.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16084-e16084
Author(s):  
Vinay Mathew Thomas ◽  
Basil Baby ◽  
Kevin Wang ◽  
Feitong Lei ◽  
Quan Chen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Incidence ◽  
Survival Rates ◽  
Age Groups ◽  
Cost Effective ◽  
Cancer Registries ◽  
Population Based ◽  
Incidence Rates ◽  
Comprehensive Overview ◽  
Colorectal Cancer Incidence

e16084 Background: Colorectal cancer (CRC) accounts for 10% of global cancer deaths yearly. It is postulated that the incidence rates are rising in developing countries like India. We present a comprehensive overview of colorectal cancer incidence in India from various regions from 2004 to 2014. Methods: We obtained data on CRC incidence from the Population Based Cancer Registries (PBCR) of the National Cancer Registry Program. We calculated age-standardized incidence rates (to WHO World Standard Population 2000) for five-year age groups for period of diagnosis (2004-05, 2006-08, 2009-11, and 2012-14). Results: From 2004 to 2014, CRC incidence rates in India increased by 20%. During 2004-2005, the incidence rate of CRC was 5.8 per 100,000 persons. It increased to 6.9 during 2012-2014. Conclusions: CRC rates are rising in India. Even though the absolute rates are low in the Indian population, the rising rates pose a problem in rising cancer morbidity in India. The rising rates can be attributed to changing lifestyles that include consumption of calorie-rich and low fibre diet, excessive use of red meat and processed foods, and physical inactivity. There is a need for cost-effective strategies to enable early diagnosis for colorectal cancer in India. Affordable and equitable treatment will help increase the 5-year survival rates of colorectal cancers. [Table: see text]

Nationwide trends in the incidence of orbital lymphoma from 1999 to 2016 in South Korea

2020 ◽  
pp. bjophthalmol-2020-316796
Author(s):  
Su Kyung Jung ◽  
Jiwon Lim ◽  
Suk Woo Yang ◽  
Young-Joo Won
Keyword(s):  
South Korea ◽  
B Cell ◽  
Incidence Rate ◽  
Cell Lymphoma ◽  
Survival Rates ◽  
B Cell Lymphoma ◽  
Population Based ◽  
Incidence Rates ◽  
Annual Percent Change ◽  
Orbital Lymphoma

Background/AimsLymphomas are the most frequent neoplasm of the orbit. However, the epidemiology of orbital lymphomas is not well reported. This study aimed to provide a population-based report on the epidemiology of orbital lymphomas and measure the trends in the incidence of orbital lymphoma cancer in South Korea.MethodsNationwide cancer incidence data from 1999 to 2016 were obtained from the Korea Central Cancer Registry. Age-standardised incidence rates and annual percent changes were calculated according to sex and histological types. The analysis according to the Surveillance, Epidemiology, and End Results summary stage classifications was performed from 2006 to 2016. Survival rates were estimated for cases diagnosed from 1999 to 2016.ResultsA total of 630 patients (median age: 54 years) with orbital lymphoma in the orbital soft tissue were included in this study. The age-standardised incidence rates increased from 0.03 to 0.08 per 100 000 individuals between 1999 and 2016, with an annual percent change of 6.61%. The most common histopathological type of orbital lymphoma was extra marginal zone B cell lymphoma, accounting for 82.2% of all orbital lymphomas during 1999–2016, followed by diffuse large B cell lymphoma (9.2%). Five-year, 10-year and 15-year overall survival (OS) of orbital lymphoma was 90.8%, 83.8% and 75.8%, respectively. OS showed a significant decrease as age increased and no significant differences between men and women.ConclusionThe incidence rate of orbital lymphoma is very low in South Korea. However, the incidence rate has increased over the past years. Orbital lymphomas have a worse prognosis as age increases.

scholarly journals Incidence and Trends of the Leading Cancers with Elevated Incidence Among American Indian and Alaska Native Populations, 2012–2016

2020 ◽  
Author(s):  
Stephanie C Melkonian ◽  
Hannah K Weir ◽  
Melissa A Jim ◽  
Bailey Preikschat ◽  
Donald Haverkamp ◽  
...  
Keyword(s):  
American Indian ◽  
Cancer Incidence ◽  
Alaska Native ◽  
Cancer Registries ◽  
Population Based ◽  
Incidence Rates ◽  
Breast Cancers ◽  
Age Adjusted Rates ◽  
Incident Cases ◽  
Hispanic White

Abstract Cancer incidence varies among American Indian and Alaska Native (AI/AN) populations, as well as between AI/AN and White populations. This study examined trends for cancers with elevated incidence among AI/AN compared with non-Hispanic White populations and estimated potentially avoidable incident cases among AI/AN populations. Incident cases diagnosed during 2012–2016 were identified from population-based cancer registries and linked with the Indian Health Service patient registration databases to improve racial classification of AI/AN populations. Age-adjusted rates (per 100,000) and trends were calculated for cancers with elevated incidence among AI/AN compared with non-Hispanic White populations (rate ratio &gt;1.0), by region. Trends were estimated using joinpoint regression analyses. Expected cancers were estimated by applying age-specific cancer incidence rates among non-Hispanic White populations to population estimates for AI/AN populations. Excess cancer cases among AI/AN populations were defined as observed minus expected cases. Liver, stomach, kidney, lung, colorectal and female breast cancers had higher incidence rate among AI/AN populations across most regions. Between 2012 and 2016, nearly 5,200 excess cancers were diagnosed among AI/AN populations, with the largest number of excess cancers (1,925) occurring in the Southern Plains region. Culturally informed efforts may reduce cancer disparities associated with these and other cancers among AI/AN populations.

Sign in / Sign up

Export Citation Format

Share Document